【摘要】 目的探讨TIP30在表皮生长因子受体-2(HER-2)阳性乳腺癌患者癌组织中表达及临床意义。方法选择接受过生物化疗(曲妥珠单抗联合紫杉醇)的HER-2阳性晚期乳腺癌患者53例,采用免疫组化法检测患者癌组织中的TIP30表达,并分析其表达与患者临床病理特征及临床疗效的关系。结果 TIP30在HER-2阳性乳腺癌组织中阳性表达率为56.6%,TIP30表达与患者的年龄、病理类型、转移部位数量及雌激素受体、孕激素受体表达无关,而与功能状态评分及临床疗效相关(P均<0.05)。53例患者化疗2个周期后,临床获益(CB)29例(CB率为54.7%)。30例TIP30阳性表达的患者中,CB 22例(73.3%);23例TIP30阴性表达的患者中,CB 7例(30.4%),两者CB率比较P<0.05。TIP30表达阳性、阴性患者的中位无进展生存期分别为11.47、4.87个月,两者比较P<0.01。结论 TIP30在HER-2阳性晚期乳腺癌患者癌组织中表达下调可能与预后不良有关,其可能作为该类患者生物化疗的疗效预测指标之一。更多还原

【Abstract】 Objective To explore the expression of TIP30 in epidermal growth factor receptor-2( HER-2)-positive advanced breast cancer and its clinical significance. Methods The expression of TIP30 was detected in 53 HER-2-positive advanced breast cancer tissues by immunohistochemistry. The tissues were obtained before biochemotherapy by Herceptin plus taxol( TAX). The relationship with clinicopathological parameters and biochemotherapy response was analyzed. Results The positive expression rate of TIP30 was 56. 6% in HER-2-positive advanced breast cancer tissues. There was no correlation between the expression of TIP30 protein and age,pathological pattern,metastasis,estrogen receptor( ER),and progestrone receptor( PR),but the expression of TIP30 was associated with the functional status score and clinical efficacy( all P <0.05). After two cycles of biochemotherapy,the clinical benefit rate( CBR) was 54. 7%. In 30 patients with positive TIP30 expression,the CBR was 73. 3%( 22 /30),by contrast,the CBR was only 30. 4% in 23 patients with negative TIP30 expression,which showed a significant difference between the two groups( all P < 0. 05). The median progression-free survival time was 11. 47 and 4. 87 months in patients with positive TIP30 expression and negative TIP30 expression,respectively( all P < 0. 01). Conclusion The down-regulated TIP30 expression in HER-2-positive advanced breast cancer may be associated with the poor prognosis,which could be an important biomarker in predicting the efficacy of biochemotherapy in patients with HER-2-positive advanced breast cancer.更多还原